Evaluation of the myocardial protection of trimetazidine during percutaneous coronary intervention:a multi-center randomized and controlled clinical study
10.3760/cma.j.issn.0578-1426.2010.06.006
- VernacularTitle:曲美他嗪对冠状动脉介入治疗患者的心脏保护作用
- Author:
Yundai CHEN
;
Likun ZHAO
;
Feng TIAN
;
Zhimin DU
;
Hong JIANG
;
Meng WEI
- Publication Type:Journal Article
- Keywords:
Coronary artery disease;
Angioplasty,transluminal,percutaneous coronary;
Cardiotonic agents
- From:
Chinese Journal of Internal Medicine
2010;49(6):473-476
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the myocardial protection effects of trimetazidine during percutaneous coronary intervention (PCI). Methods 101 patients from 5 hospitals with stable or unstable angina pectoris were enrolled in this study. All the patients were randomized into two groups: a trimetazidine group (n = 54) and a control group ( n = 47). The trimetazidine group received oral trimetazidine 20 mg three times a day for (5±2 ) days before coronary angiography and a loading dose of 60 mg 30 minutes before PCI. The daily routine dosage was continued for 4 weeks after the procedure. The control group received similar treatment except trimetazidine. For each patient, the angina pectoris attacks, CK-MB,electrocardiogram and echocardiogram were noted. Results Angina did not occur in trimetazidine group during the procedure but occurred in 12 patients( 25.5% ) in the control group( P <0.001 ). The changes of ST-segment and T wave during balloon dilatation in PCI procedure were less in the trimetazidine group (60.8% vs 78.3% , P < 0.05). Ejection fraction in the trimetazidine group was higher than that in the control group 4 weeks [ ( 66.6±7.1 ) % vs ( 63.0±7.7 ) % , P = 0.03 ] after PCI. Conclusion Trimetazidine could reduce the frequency of angina pectoris attacks and myocardial damage during PCL It also improves left ventricular function during follow-up after PCL
